Here’s news of a big (phase III) trial showing that ocrelizumab (anti-CD20) slows acquisition of disability in PPMS and RRMS. I want to be on this drug.
OH yeh! I do hope you get it darlin!
Now all we have to wait for is licensing … and NICE approval … and all our neurologists to get on board with it … and the setting up of prescribing centres … and training of MS nurses … So it should only take another few years then!!!
But still, excellent news at last.